☆ 3.8 Article

EGFR point mutation confers resistance to gefitinib in a patient with non-small-cell lung cancer

NATURE CLINICAL PRACTICE ONCOLOGY (2005)

Get Full Text
Add to Collection

Journal

NATURE CLINICAL PRACTICE ONCOLOGY
Volume 2, Issue 6, Pages 296-297

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/ncponc0200

Keywords

EGFR; erlotinib; gefitinib; mutation; non-small-cell lung cancer

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.